TheNote
ViiV Healthcare receives compl... Note
GooglePlay AppStore
GSK press releases

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

ViiV Healthcare received a CRL from the FDA regarding its application for cabotegravir and rilpivirine.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-complete-response-letter-from-us-fda-for-use-of-investigational-cabotegravir-and-rilpivirine-long-acting-regimen-in-the-treatment-of-hiv/ gsk.com
RSS Hunter RSS Hunter • Dec 21, 2019